ID: ALA298415

Max Phase: Preclinical

Molecular Formula: C19H17N5O2

Molecular Weight: 347.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N=C(N)c1ccc(Oc2cccc(Oc3ccc(C(=N)N)cc3)n2)cc1

Standard InChI:  InChI=1S/C19H17N5O2/c20-18(21)12-4-8-14(9-5-12)25-16-2-1-3-17(24-16)26-15-10-6-13(7-11-15)19(22)23/h1-11H,(H3,20,21)(H3,22,23)

Standard InChI Key:  VATCDKFGSBVBMX-UHFFFAOYSA-N

Associated Targets(Human)

Coagulation factor X 9693 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Thrombin 11687 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Trypsin 2137 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matriptase 677 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Trypsin I 1205 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

L6 7924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Trypanosoma brucei rhodesiense 7991 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Plasmodium falciparum 966862 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 347.38Molecular Weight (Monoisotopic): 347.1382AlogP: 3.23#Rotatable Bonds: 6
Polar Surface Area: 131.09Molecular Species: BASEHBA: 5HBD: 4
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 6#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 11.90CX LogP: 2.79CX LogD: -2.03
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.40Np Likeness Score: -0.40

References

1. Phillips G, Davey DD, Eagen KA, Koovakkat SK, Liang A, Ng HP, Pinkerton M, Trinh L, Whitlow M, Beatty AM, Morrissey MM..  (1999)  Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.,  42  (10): [PMID:10346927] [10.1021/jm980667k]
2. Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM..  (1998)  Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.,  41  (19): [PMID:9733480] [10.1021/jm980280h]
3. Goswami R, Mukherjee S, Wohlfahrt G, Ghadiyaram C, Nagaraj J, Chandra BR, Sistla RK, Satyam LK, Samiulla DS, Moilanen A, Subramanya HS, Ramachandra M..  (2013)  Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.,  (12): [PMID:24900621] [10.1021/ml400213v]
4. Arafa RK, Ismail MA, Wenzler T, Brun R, Paul A, Wilson WD, Alakhdar AA, Boykin DW..  (2021)  New antiparasitic flexible triaryl diamidines, their prodrugs and aza analogues: Synthesis, in vitro and in vivo biological evaluation, and molecular modelling studies.,  222  [PMID:34146914] [10.1016/j.ejmech.2021.113625]

Source